{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:34:30Z","timestamp":1790922870855,"version":"4.1.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Winn Career Development"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA077598"],"award-info":[{"award-number":["P30 CA077598"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department Of Defense","doi-asserted-by":"crossref","award":["W81XWH-22-2-0025"],"award-info":[{"award-number":["W81XWH-22-2-0025"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Clonal hematopoiesis (CH) may be inferred from clinical next-generation sequencing (NGS) of tumor tissue. The clinical significance of inferred CH when detected as part of routine tumor sequencing is not well established and it is unknown whether or not CH is associated with other somatic mutations in tumors of men with prostate cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a retrospective review of clinical-grade NGS results from primary prostate tissue at a single institution. NGS reports were reviewed for the presence of pathogenic mutations in a panel of 27 genes commonly known to be mutated in CH. Overall survival from time of diagnosis and association with somatic alterations were interrogated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 396 patients were included, with a median follow-up of 7.8 years (range 0.2-21.4 years). Approximately 12% of patients had inferred CH detected (n\u2005=\u200546) with ASXL1, TET2, and DNMT3A being the most commonly affected genes. In univariate analysis, those with inferred CH had an 81% increased risk of death compared to those without inferred CH (hazard ratio 1.8, 95% CI 1.1, 3.1, P\u2005=\u2005.03). This was attenuated after controlling for age at diagnosis and race (HR 1.1, 95% CI 0.6, 2.0, P\u2005=\u2005.77). Those with inferred CH were more likely to have pathogenic somatic mutations in PIK3CA (15% vs 4%), CTNNB1 (13% vs 2%) and BRCA1 (4% vs 0.3%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Inferred CH is commonly detected on tumor-tissue NGS testing but does not clearly have a negative prognostic impact after adjusting for age. It may also be associated with the identification of other somatic driver mutations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf049","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T11:46:07Z","timestamp":1745322367000},"source":"Crossref","is-referenced-by-count":4,"title":["Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomes"],"prefix":"10.1093","volume":"30","author":[{"given":"Yasaman","family":"Iranmanesh","sequence":"first","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Omar","sequence":"additional","affiliation":[{"name":"UPMC Western Maryland, Department of Internal Medicine. Cumberland, MD 21502 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Rasouli","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Baras","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Pasca","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz P","family":"Gondek","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Ling","family":"Tsai","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel R","family":"Denmeade","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Carducci","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channing J","family":"Paller","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Markowski","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Urology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario A","family":"Eisenberger","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota , Minneapolis, MN 55455 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2653-4110","authenticated-orcid":false,"given":"Catherine H","family":"Marshall","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD 21287 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"2025042207460022400_CIT0001","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"2025042207460022400_CIT0002","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/s41375-020-0869-y","article-title":"Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders","volume":"34","author":"Midic","year":"2020","journal-title":"Leukemia"},{"key":"2025042207460022400_CIT0003","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"2025042207460022400_CIT0004","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"2025042207460022400_CIT0005","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"2025042207460022400_CIT0006","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1182\/blood-2018-03-840629","article-title":"Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens","volume":"131","author":"Severson","year":"2018","journal-title":"Blood"},{"key":"2025042207460022400_CIT0007","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1200\/jco.2021.39.15_suppl.3009","article-title":"Prevalence of inferred clonal hematopoiesis (CH) detected on comprehensive genomic profiling (CGP) of solid tumor tissue or circulating tumor DNA (ctDNA)","volume":"39","author":"Antonarakis","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025042207460022400_CIT0008","doi-asserted-by":"publisher","first-page":"e17001","DOI":"10.1200\/jco.2021.39.15_suppl.e17001","article-title":"Clonal hematopoiesis in prostate cancer inferred from somatic tumor profiling","volume":"39","author":"Marshall","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025042207460022400_CIT0009","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"2025042207460022400_CIT0010","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","article-title":"Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"2025042207460022400_CIT0011","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1158\/1078-0432.CCR-21-0121","article-title":"A subset of localized prostate cancer displays an immunogenic phenotype associated with losses of key tumor suppressor genes","volume":"27","author":"Calagua","year":"2021","journal-title":"Clin Cancer Res."},{"key":"2025042207460022400_CIT0012","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-24-080","article-title":"Clonal hematopoiesis and clinical outcomes in metastatic castration-resistant prostate cancer patients given androgen receptor pathway inhibitors (Alliance A031201)","volume":"30","author":"Jensen","year":"2024","journal-title":"Clin Cancer Res."},{"key":"2025042207460022400_CIT0013","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/hmg\/ddac214","article-title":"Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men","volume":"32","author":"Wang","year":"2023","journal-title":"Hum Mol Genet"},{"key":"2025042207460022400_CIT0014","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-22-1622","article-title":"Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience","volume":"28","author":"Marmouset","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025042207460022400_CIT0015","doi-asserted-by":"publisher","first-page":"10522","DOI":"10.1200\/jco.2023.41.16_suppl.10522","article-title":"Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers","volume":"41","author":"Marshall","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025042207460022400_CIT0016","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","article-title":"Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference","volume":"7","author":"Jensen","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025042207460022400_CIT0017","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/s41375-024-02253-3","article-title":"Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer","volume":"38","author":"Arends","year":"2024","journal-title":"Leukemia"},{"key":"2025042207460022400_CIT0018","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pros.24712","article-title":"Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer","volume":"84","author":"Marshall","year":"2024","journal-title":"The Prostate."},{"key":"2025042207460022400_CIT0019","doi-asserted-by":"publisher","first-page":"e2300567","DOI":"10.1200\/PO.23.00567","article-title":"Repeat next-generation sequencing testing on progression in men with metastatic prostate cancer can identify new actionable alterations","volume":"8","author":"Park","year":"2024","journal-title":"JCO Precis Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/4\/oyaf049\/62982346\/oyaf049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/4\/oyaf049\/62982346\/oyaf049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T11:46:09Z","timestamp":1745322369000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf049\/8117450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf049","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,4]]},"article-number":"oyaf049"}}